Biotech Mailbag: Buy Dip in T2 Biosystems?
Plus, what's going on with Lexicon Pharmaceuticals?
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading today, for the September 15th expiration.
Investors in Lexicon Pharmaceuticals, Inc. saw new options become available this week, for the August 18th expiration.
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2018 expiration.
Karyopharm Therapeutics falls 18%; Lexicon rises on drug approval.
Here's why to check out Dynavax Technologies as well Lexicon, Supernus and Acadia Pharmaceuticals.
M&A, drug approvals and Trump are all on my watch list.
Here are some names that have caught our eye.
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2017 expiration.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Lexicon Pharmaceuticals, Inc. , where a total volume of 6,103 contracts has been traded thus far today, a contract volume which is representative of approximately 610,300 underlying shares (given that every 1 contract represents 100 underlying shares).
The most recent short interest data has been released for the 09/30/2016 settlement date, which shows a 2,011,299 share increase in total short interest for Lexicon Pharmaceuticals, Inc. , to 14,608,790, an increase of 15.97% since 09/15/2016.
Investors in Lexicon Pharmaceuticals, Inc. saw new options begin trading this week, for the August 19th expiration.
Here's a technical look at how to trade seven stocks rising on unusual volume.
The most recent short interest data has been released by the NASDAQ for the 12/31/2015 settlement date, which shows a 1,541,247 share decrease in total short interest for Lexicon Pharmaceuticals, Inc. , to 12,802,214, a decrease of 10.75% since 12/15/2015.
Here are the 10 stocks in the biotech sector which had the best third-quarter.
So where does the market go from here?
Anxiety over being left behind is building.
We have a few more days of this slow trading, and it is unlikely to change much.
Signs of support on the S&P, but there is a lot of uncertainty.
On a big gap down open on news like the jobs report, you'd expect a quick oversold bounce. We got a little bounce, but two problems are sidelining buyers.
When and Where Will We Find a Bottom?
Market is following textbook corrective action.
But bears finally have some momentum heading into a seasonally poor month.